An Open-Label, Long-Term Extension Study of the Safety of Somavaratan (VRS-317) in Adults With Growth Hormone Deficiency (GHD)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Somavaratan (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Versartis
- 21 Nov 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2017.
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated